Innate Pharma
IPH | XPAR
Overview
Corporate Details
- ISIN(s):
- FR0010331421 (+1 more)
- LEI:
- 9695002Y8420ZB8HJE29
- Country:
- France
- Address:
- 117 AVENUE DE LUMINY, 13009 MARSEILLE
- Website:
- http://www.innate-pharma.com/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Innate Pharma’s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need. Innate is a pioneer in the understanding of natural killer cell (NK cell) biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-05-23 07:00 |
Declaration of Voting Results & Voting Rights Announcements
Inside Information / Other news releases
|
English | 232.8 KB | |
| 2025-05-23 07:00 |
Regulatory News Service
Inside Information / Other news releases
|
English | 230.4 KB | |
| 2025-05-23 07:00 |
Inside Information Statement
Informations privilégiées / Autres communiqués
|
French | 188.7 KB | |
| 2025-05-19 07:00 |
Inside Information Statement
Inside Information / Other news releases
|
English | 181.7 KB | |
| 2025-05-19 07:00 |
Regulatory News Service
Informations privilégiées / Autres communiqués
|
French | 148.3 KB | |
| 2025-05-15 07:00 |
Regulatory News Service
Inside Information / Other news releases
|
English | 170.4 KB | |
| 2025-05-15 07:00 |
Inside Information Statement
Informations privilégiées / Autres communiqués
|
French | 123.4 KB | |
| 2025-05-13 07:00 |
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
|
French | 251.1 KB | |
| 2025-05-13 07:00 |
Earnings Release
Inside Information / News release on accounts, results
|
English | 228.2 KB | |
| 2025-05-12 07:00 |
Declaration of Voting Results & Voting Rights Announcements
Total number of voting rights and capital / Information on the total number of …
|
English | 141.6 KB | |
| 2025-05-12 07:00 |
Declaration of Voting Results & Voting Rights Announcements
Total du nombre de droits de vote et du capital / Information relative au nombr…
|
French | 116.5 KB | |
| 2025-05-06 07:00 |
Earnings Release
Informations privilégiées / Autres communiqués
|
French | 180.1 KB | |
| 2025-05-06 07:00 |
Report Publication Announcement
Inside Information / Other news releases
|
English | 228.4 KB | |
| 2025-05-02 15:22 |
Regulatory News Service
Franchissement de seuils
|
French | 112.9 KB | |
| 2025-04-30 17:30 |
Report Publication Announcement
Terms of availability of a registration document or its updates
|
English | 122.4 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-10 | N/A | Other | Buy | 6,000 | N/A |
| 2024-01-02 | N/A | Other | Buy | 20,000 | N/A |
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
1NKEMIA | Spain | IKM | |
|
2cureX AB | Sweden | 2CUREX | |
|
4SC AG | Germany | VSC | |
|
Abera Bioscience AB | Sweden | ABERA | |
|
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
|
AB Science | France | AB | |
|
Acticor Biotech | France | ALACT | |
|
Active Biotech | Sweden | ACTI | |
|
AcuCort AB | Sweden | ACUC |